Think President Donald Trump's proposal to slap price tags on drug advertising is all talk and no action? Think again. Over the past couple of weeks, the idea has gained steam—and bipartisan backing, including from Democrats often critical of the president. So much so, in fact, that a bill containing the provision could see a Senate vote this week.

As the CMS charts a path to level pay for outpatient services, it's also leading toward a head-to-head battle with powerful hospital lobbying groups as some providers win and lose with site-neutral payments.

The U.S. is grappling with how to rein in high drug prices. Unfortunately, most of the proposed solutions work better on a bumper sticker than in reality. The debate, however, tends to ignore a key player -- the prescribing doctor -- who could have a central role in a more sustainable approach to better value in drug pricing.

One year ago, with the flick of his thumb, Sen. John McCain (R-Ariz.) foiled the Republican Party’s quest to undo the Affordable Care Act and fulfill a seven-year promise to remake the health-care system.

Red-state Democrats are signaling some solidarity with the rest of the caucus on at least one policy issue flaring in the fight over Brett Kavanaugh’s Supreme Court nomination. Lawmakers including Sens. Joe Manchin (WV), Joe Donnelly (IN), and Heidi Heitkamp (ND) — all Democrats representing states that Donald Trump won by a wide margin in 2016 — are among those backing a new Senate resolution aimed at defending the constitutionality of the Affordable Care Act.

Anthem’s decision to exit some individual markets under the Affordable Care Act in favor of growing its Medicare business helped boost profits in the health insurer’s second quarter.